Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 2

Sponsor

Conditions

Neuromuscular Manifestations 2Neuromuscular Diseases 2Myasthenia Gravis 2

Interventions

pembrolizumab 1034Carboplatin 973Paclitaxel 942Gemcitabine 799Cisplatin 759Docetaxel 699Bevacizumab 637Nivolumab 520Pemetrexed 509Cyclophosphamide 476Capecitabine 475Fluorouracil 425Dexamethasone 410Rituximab 392Oxaliplatin 352Injections 349Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 252Ipilimumab 244Doxorubicin 242Lenalidomide 231Fulvestrant 226fludarabine 221durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Diagnostic Self Evaluation × Clear all
NCT06381284 2025-03-25

Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment

ZS Associates

Completed
215 enrolled

Myasthenia Gravis, Neuromuscular Diseases, Neuromuscular Manifestations

NCT06866483 2025-03-10

Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment

ZS Associates

Recruiting
1,000 enrolled

Myasthenia Gravis, Neuromuscular Diseases, Neuromuscular Manifestations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡